Pain Therapeutics Phase I Study Positive

Pain Therapeutics (PTIE) announced early on Wednesday that its phase I clinical study of the abuse resistant opioid painkiller, PTI-202, showed positive results.

The study was aimed at investigating the safety and tolerability of PTI-202.

The company is focused on research and development of its opioid painkiller portfolio that exhibit non-abuse potential as compared to traditional opioids on the market.

Pain Therapeutics was chosen as a BioHealth Investor Stock Pick back on November 19.